Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Mar;33(1):78-81.
doi: 10.5455/msm.2021.33.78-81.

Adalimumab in Treatment of Uveitis in Pediatric Behcet's Disease-a Case Report

Meliha Halilbasic  1 , Amra Nadarevic Vodencarevic  1 , Almira Cosickic  2 , Amir Halilbasic  2 , Arnes Cabric  3
Affiliations
Case Reports

Adalimumab in Treatment of Uveitis in Pediatric Behcet's Disease-a Case Report

Meliha Halilbasic et al. Mater Sociomed. 2021 Mar.

Abstract

Introduction: Behcet's Disease (BD) is an inflammatory disease characterized by multisystemic involvement and featured by a chronic, relapsing disease course. Recurrent ocular inflammation and macular involvement may lead to severe loss of visual acuity. Prolonged use of local and systemic corticosteroids lead to numerous side effects and complications. Very often other immunosuppressive therapies are needed. Biologic agents are promising for the treatment of Behcet's disease-associated uveitis.

Aim: To report successful treatment of paediatric uveitis due to incomplete Behçet's disease with administration of adalimumab, after failing to react to all other modalities of treatment.

Case report: We present the case of a 15-year-old girl who was treated for reccurent uveitis in both eyes with developed complications on anterior and posterior ocular segment. She was earlier treated with topical and systemic steroids for uveitis, laser photocoagulation and methotrexate, however, relapses occurred inspite all treatment modalities. Patient was diagnosed with incomplete Behcet's disease, and adalimumab therapy was initiated. Inflammation was well-controlled by adalimumab administration without need for local or systemic corticosteroids.

Conclusion: Adalimumab is effective for treating children with Behcet's disease-associated uveitis. Control of ocular inflammation in our case was achieved without need for continuing local or systemic corticosteroids, thus preventing further complications and possible significant vision loss.

Keywords: Behcet’s disease; adalimumab; ophthalmology; pediatric uveitis.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1.
Figure 1.. Slit lamp image of right and left eye, with posterior synechiae and posterior cortical cataracts
Figure 2.
Figure 2.. Ultrasound of right and left eye with vitreus inflammatory reaction
Figure 3.
Figure 3.. Fluorescein angiography of right and left eye
Figure 4.
Figure 4.. SD OCT showing intraretinal cysts, more on right eye
Figure 5.
Figure 5.. SD OCT after 12 months with adalimumab
See this image and copyright information in PMC

References

    1. Yıldız M, Köker O, Adrovic A, Şahin S, Barut K, Kasapçopur Ö. Pediatric Behçet’s disease–clinical aspects and current concepts. Eur J Rheumatol. 2019;7(Suppl 1):1–10. doi: 10.5152/eurjrheum.2019.19121. - DOI - PMC - PubMed
    1. Tong B, Liu X, Xiao J, Su G. Immunopathogenesis of Behcet’s disease. Front Immunol. 2019;10:665. doi: 10.3389/fimmu.2019.00665. - DOI - PMC - PubMed
    1. Greco A, De Virgilio A, Ralli M, et al. Behcet’s disease: new insights into pathophysiology, clinical features and treatment options. Autoimmun Rev. 2018;17(6):567–575. doi: 10.1016/j.autrev.2017.12.006. - DOI - PubMed
    1. Kone-Paut I, Yurdakul S, Bahabri SA, Shafae N, Ozen S, Ozdogan H, et al. Clinical features of Behcet’s disease in children: An international collaborative study of 86 cases. J Pediatr. 1998;132:721–725. doi: 10.1016/S0022-3476(98)70368-3. - DOI - PubMed
    1. Verity DH, Marr JE, Ohno S, Wallace GR, Stanford MR. Behcet’s disease, the Silk Road and HLA-B51: Historical and geographical perspectives. Tissue Antigens. 1999;54 doi: 10.1034/j.1399-0039.1999.540301.x. - DOI - PubMed

Publication types

LinkOut - more resources